Tag: Biocad

BIOCAD is Russia’s leading innovative biotechnology company which combines a world-class research and development center, ultra-modern pharmaceutical and biotechnology manufacturing facilities, and pre-clinical and clinical research infrastructure compliant with international standards.

BIOCAD is one of the few world’s full-cycle drug development and manufacturing companies, doing everything from new molecules discovery and genetic engineering to large-scale commercial manufacturing and marketing support. BIOCAD’s medicines are used to treat the most complex health conditions, such as cancer, HIV and Hepatitis C infections, multiple sclerosis and other disorders.

The company employs about 1000 people, 300 out of them scientists and researchers. In 2014 BIOCAD’s sales tripled and reached $200 million, while total amount of long-term international contracts exceeded half a billion US dollars. BIOCAD has subsidiaries in the US, Brazil, China, India, Singapore, and other countries.

BIOCAD has established a wide international presence – through a network of its subsidiaries and partnerships – in Belarus, Ukraine, Brazil, India, China and the United States. BIOCAD’s international strategy is to reinforce its own market leadership position in Russia while entering new markets, thus leveraging and balancing R&D, sales, procurement and logistic synergies across several continents. Every subsidiary or a partner company successfully combines R&D, market evaluation and business development activities, and provides access to talents, innovations and market opportunities of the region.

BIOCAD will continue to supply biosimilar of rituximab to Vietnam

In March, BIOCAD, a biotech company, has for the second time received a quota to supply a biosimilar of rituximab to Vietnam. This means that BIOCAD partners will continue to supply local hospitals wi...

BIOCAD launches a drug labeling information system

In mid-March, BIOCAD, a biotech company, launched in operating mode a Track&Trace system for its three products. This is a pilot project implemented as part of the experiment to label certain medi...

Pharmasyntez and Biocad are in top 10 Russian hospital procurement manufacturers

According to the hospital audit of Russian pharmaceutical market conducted by DSM Group, in 2016, 882.2 million packages of medicinal products worth 221.9 billion rubles were purchased for hospitals i...

Equipment for labelling drugs will not cost more than 150,000 euros

The cost of equipment required for labelling drugs on one production line of a pharmaceutical plant does not exceed €150,000. This was reported in an interview with TASS by Dmitry Morozov, General Dir...

BIOCAD’s first biosimilar of interferon beta-1a approved in Russia

The Ministry of Health (MoH) of the Russian Federation has awarded Biocad marketing authorization for its interferon beta-1a biosimilar, a knockoff of Biogen's Rebif® that is a key component in treatm...

BIOCAD will invest 20 bln rubles in production development

In the near 3-5 years BIOCAD Company is going to invest 20 bln rubles in development of its production facilities in St.Petersburg. Biotechnological company BIOCAD has started several projects at once...

Biocad will launch new anti-cancer drug in Russia

Russia’s leading biotech firm Biocad is finishing clinical trials of a new anti-cancer drug that will soon appear in the Russian market and will be able to compete with imported analogues, according t...

Vladimir Putin and Nursultan Nazarbayev visited the scientific-research center BIOCAD

"Biocad" Director General Dmitry Morozov gives an explanation
Presidents of Russia Vladimir Putin and President of Kazakhstan Nursultan Nazarbaev visited the plant and scientific-research center BIOCAD Russian biotech company in the special economic zone "Neudor...

Advanced rheumatoid arthritis medicine developed in Russia

Biotechnological company BIOCAD has developed innovative medicine for treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and other autoimmune diseases. According to scientists forecast,...